Toshihide Nishibata

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Hiroshi Hirai, Yoshikazu Iwasawa, Megumu Okada et al. · Molecular Cancer Therapeutics · 2009 · 550 citations

Life Sciences, Molecular Biology, Pharmacology +17

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

Hiroshi Hirai, Tsuyoshi Arai, Megumu Okada et al. · Cancer Biology & Therapy · 2010 · 236 citations · Full text

Medicine, Oncology, Pharmacology +17

Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity

Yoko Yamamoto, Yasuo Tsutsumi, Yasuo Yoshioka et al. · Nature Biotechnology · 2003 · 208 citations

Life Sciences, Biochemistry, Biotechnology +13

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Shinji Mizuarai, Kazunori Yamanaka, Hiraku Itadani et al. · Molecular Cancer · 2009 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17

Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency

Yasuo Yoshioka, Yasuo Tsutsumi, Shinji Ikemizu et al. · Biochemical and Biophysical Research Communications · 2004 · 53 citations

Medicine, Medicinal Chemistry, Oncology +10